- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fewer Recalls with Synthesized Mammography Plus Digital Breast Tomosynthesis
The use of synthesized mammography instead of additional full-field digital mammography has no significant effect on biopsy rate.
Synthesized mammography (SM) with digital breast tomosynthesis (DBT) lowers recall rate, according to a study published in the journal Academic Radiology.
Researchers from Johns Hopkins University in Baltimore, Md., and the University of Wisconsin in Madison sought to evaluate the screening performance of DBT combined with SM versus combined with full-field digital mammography (FFDM).
The researchers retrospectively reviewed 7,745 screening studies utilizing FFDM plus DBT and 14,776 with SM plus DBT. They compared recall rate, biopsy rate, positive predictive value 1 (PPV1), positive predictive value 3 (PPV3), and cancer detection rate (CDR) between the two groups.
The results showed the overall recall rate was 7.06 percent in the SM + DBT cohort, which was significantly lower compared to 7.63 percent in the FFDM + DBT cohort. There was no difference in biopsy rate, PPV1, PPV3, or CDR between the two groups.
The researchers concluded that their findings support the use of SM for patients undergoing screening with DBT.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.
